Alan W. Partin

Genetics · 2001–2016

A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Genetics — 10 citations into it

Whom Alan W. Partin trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Sunil Rao

Who trusts Alan W. Partin overall

1. A. Heidenreich

Papers from Alan W. Partin's perspective

Ordered by how strongly the researchers Alan W. Partin trusts endorse each paper. Same corpus, a different order for every researcher.

1. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis
2. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. (Journal of the American Medical Association (JAMA))
3. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. (Journal of Clinical Oncology)
4. European Organization for Research and Treatment of Cancer
5. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. (Journal of Clinical Oncology)
6. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. (New England Journal of Medicine)
7. A common variant associated with prostate cancer in European and African populations (Nature Genetics)
8. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. (New England Journal of Medicine)
9. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes (Nature Genetics)
10. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke (Nature Genetics)

Their papers

• A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. (2016) — 625 citations
• PREDICTING FIFTEEN-YEAR CANCER-SPECIFIC MORTALITY BASED ON THE PATHOLOGICAL FEATURES OF PROSTATE CANCER (2011) — 637 citations
• Ligand-independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone Refractory Prostate Cancer (2009) — 1,071 citations
• Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. (2008) — 667 citations
• Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 (2007) — 910 citations
• Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. (2005) — 1,402 citations
• Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. (2003) — 829 citations
• Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. (2002) — 1,074 citations
• Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. (2001) — 1,074 citations